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The term microalbuminuria – a urinary albumin excretion
(UAE) between 20 and 200 lg/min – has been introduced to
identify subjects at increased risk of renal and cardiovascular
disease. However, the relationship between albuminuria and
risk is not restricted to the microalbuminuric range and
extends to as low as 2–5 lg/min. On the contrary, the increase
of UAE above 200 lg/min (macroalbuminuria) heralds the
onset of proteinuria (urinary protein excretion above
0.5 g/24 h) and progressive renal and cardiovascular disease.
Albuminuria is a component of the metabolic syndrome and
may represent a marker of the increased risk of renal and
cardiovascular disease associated with insulin resistance and
endothelial dysfunction. Proteinuria is a sign of established
kidney damage and plays a direct pathogenic role in the
progression of renal and cardiovascular disease. Albuminuria
reflects functional and potentially reversible abnormalities
initiated by glomerular hyperfiltration, proteinuria, a
size-selective dysfunction of the glomerular barrier normally
associated with glomerular filtration rate (GFR) decline that
may result in end-stage renal disease. Thus, the limit of
200 lg/min segregates patients with albuminuria or
proteinuria who are at quite different risk. Among subjects
with albuminuria, however, there is a continuous relationship
between albumin excretion and risk and no lower bound
between normal albuminuria and microalbuminuria can
be identified that segregates subjects at different risk.
Thus, the terms microalbuminuria and macroalbuminuria
could be replaced by the concepts of albuminuria- and
proteinuria-associated diseases. Future studies are needed
to identify levels of albuminuria below which therapy is no
longer beneficial.
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WHY MEASURING ALBUMINURIA?
It is now 40 years since Keen et al.1 had reported an increase
in urinary albumin excretion (UAE) in ‘newly detected
hyperglycemics’. The term microalbuminuria, however, first
appeared in the medical literature in 1981, used by Viberti2
and Svendsen,3 to describe a UAE below the detection limit of
a standard dipstick, but at a level that, as reported by
Mogensen et al. in 1986,4 was highly predictive of future
overt nephropathy in patients with type I diabetes. Shortly
thereafter, it became evident that microalbuminuria pre-
dicted mortality, largely from cardiovascular events, in
patients with type II diabetes.5 Since then, microalbuminuria
– defined as a UAE between 20 and 200 mg/min or 30 and
300 mg in overnight and 24 h urine collections, respectively –
has been identified as a newly recognized cardiovascular and
renal risk factor in both diabetic and non-diabetic subjects.6,7
However, although the lower bound was chosen because 95%
of ‘normal’ individuals had excretion rates below that limit, it
was recognized that risk of cardiovascular events and of
progression to overt nephropathy was elevated also in
subjects in the ‘high normal’ range.8–10 Similar to the
relationship between blood pressure and risk of cardiovas-
cular events, mounting evidence indicates a continuous
relationship between UAE and risk. And like blood pressure,
the concept of a threshold level to define normality is
inconsistent with epidemiological data.11 Indeed, post hoc
analyses of randomized trials in high-risk individuals as well
as community-based cohort studies all indicate that incre-
mental increases in albuminuria within the ‘normal’ range
carry higher risks of nephropathy or cardiovascular
events.8–10 Data from the BErgamo NEphrologic Diabetes
Complications Trial12 showed that high normal albuminuria
is the strongest predictor of the onset of microalbuminuria in
patients with type II diabetes. (Perna et al., personal
communication). The Heart Outcome Prevention Evaluation
study8 also showed that the relationship between albuminuria
and experiencing a cardiovascular event extends to as low as
0.5 mg/mmol (albumin/creatinine ratio (A/C)). On the same
line are data from the Losartan Intervention For End point
reduction in hypertension study9 and several population
studies,10,13,14 In particular, the Framingham Heart Study
found that 6-year risk of cardiovascular disease was threefold
higher in nonhypertensive, non-diabetic subjects with
urinary A/C above the gender-specific median (3.9 mg/min
for men and 7.5 mg/min for women) than in those with
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urinary A/C below the median.13 The above evidence led
Forman and Brenner11 to suggest that ‘Microalbuminuria is
another term that should now be eliminated from our
lexicon, as there are ample data to suggest that albuminuria
in the ‘normal’ range carries significant risk of cardiovascular
events’. A further argument in favor of this is that the term
microalbuminuria is also incorrect, since it should reflect
small albumin molecules, and not small amounts of albumin.
This is further confusing owing to the growing evidence that,
in addition to the whole molecule, ‘normal’ urine may
contain different immunoreactive moieties and albumin
fragments.15 Thus, the concept of normal or abnormal
albuminuria should be abandoned and the unifying term of
albuminuria could be used to describe measurable amounts
of albumin in the urine. On the other end, UAE above
the limit of 200 mg/min appears to clearly identify a
different subgroup of patients with progressive renal disease
and a cardiovascular mortality rate that exceeds by about
sixfolds the rate observed in subjects with lower levels of
albuminuria or no evidence of urinary abnormalities.16
Notably, in these patients, albuminuria is invariably asso-
ciated with proteinuria and worsening renal function.17 Renal
insufficiency and overt proteinuria may cause volume
overload and worsen hypertension, dislipidemia, and en-
dothelial dysfunction, all of which may independently
sustain the excess renal and cardiovascular mortality in this
typology of patients.18
ALBUMINURIA: A CONSEQUENCE OF INSULIN RESISTANCE?
Albuminuria is often associated with the metabolic
syndrome, a syndrome of insulin resistance, obesity,
hypertension, dislipidemia, and increased renal and cardio-
vascular morbidity. Several evidences suggest that insulin
resistance precedes and probably contributes to the develop-
ment of microalbuminuria in type I diabetic patients,19 as
well as in non-diabetic subjects.20 Data in type II diabetic
patients, however, were less clear.20,21 The hypothesis of an
association between insulin resistance and microalbuminuria
was recently revived by a cross-sectional study showing
that in a large cohort of type II diabetic patients, the
homeostasis model assessment index, a surrogate of insulin
sensitivity, was significantly associated with the A/C ratio
measured in spot urine collections.22 To formally test
this possibility, we compared the total-body glucose disposal
rate, quantified by means of a euglycemic hyperinsulinemic
clamp technique, in 50 matched pairs of type II diabetic
patients with micro- or normo-albuminuria.23 Data showed
that subjects with microalbuminuria were more insulin
resistant than those with a normal urinary albumin
excretion, and that the magnitude of insulin resistance was
independently associated with microalbuminuria. Of
interest, there was a clear association between more
severe insulin resistance and microalbuminuria also in
the subgroup of patients with normal blood pressure
considered separately from those with arterial hypertension.
Altogether, these findings lend support to the possibility that
insulin resistance is directly associated with albuminuria,
regardless of its relationships with arterial hypertension. On
the other hand, finding in a collateral study that insulin
sensitivity was similar in patients with macro- or micro-
albuminuria and was not correlated with the degree of
urinary albumin excretion confirmed that increased albumi-
nuria is not per se a primary determinant of insulin
resistance.
Thus, increased albuminuria could be taken as an
indicator of insulin resistance and of the increased renal
and cardiovascular risk (the cardio-renal syndrome) asso-
ciated with the metabolic syndrome.
WHY SHOULD INSULIN RESISTANCE ENHANCE
ALBUMINURIA?
The role of endothelial dysfunction
Insulin resistance has been related to endothelial dys-
function.24,25 Endothelial cells release both relaxing and
contracting factors that modulate vascular smooth muscle
tone and also participate in the pathophysiology of essential
hypertension.26 Under physiological conditions, there is a
balanced release of endothelial-derived relaxing and
contracting factors, but this delicate balance is altered in
conditions frequently associated with albuminuria such as
hypertension, diabetes, obesity, thereby contributing to
further progression of vascular and end-organ damage.27 In
particular, endothelial damage/dysfunction, leading to de-
creased bioavailability of nitric oxide, impairs endo-
thelium-dependent vasodilation, which may contribute
to increase the arterial blood pressure26 and to accelerate
micro- and macrovascular disease.26 Moreover, damaged
endothelial cells are presumably more sensitive to the
injurious effects of further insults, such as elevated blood
pressure, analogue to the increased susceptibility of glomeruli
to higher blood pressure in diabetes mellitus, which, in turn,
may further contribute to endothelial dysfunction.28 Endo-
thelial dysfunction has also been associated with an increased
permeability of the vascular endothelial cell layer29 to
circulating macromolecules, including lipoproteins, such as
light-density lipoproteins, that have been correlated to
subsequent atherogenesis.30 This has been attributed to
changes in cell surface electrostatic charge.31 We recently
reported that a nitric-oxide releasing moiety, nitro-aspirine,
unlike aspirin, ameliorated hypertension, albuminuria, and
whole blood glucose disposal rate in hypertensive type II
diabetic patients with albuminuria and insulin resistance.32
This supports the hypothesis that defective nitric-oxide
bioavailability may play a role in the pathogenesis of
microvascular damage in diabetes and may be related with
insulin resistance. Actually, insulin therapy may improve
endothelium-dependent and endothelium-independent vaso-
dilatation,33 and amelioration of insulin resistance may
reduce arterial blood pressure and albuminuria.34 Other
factors, however, may play a role, as intensified insulin
therapy does not invariably result in improved endothelial
function.35
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The role of renal albumin handling
A defective production of heparan sulfate proteoglycans has
been observed in glomeruli of diabetic rats.36 Proteoglycans
are ubiquitous extracellular proteins that serve a variety of
functions throughout the organism, including the main-
tenance of the glomerular filtration barrier. Decreased levels
of proteoglycans may result in a decreased content of
negative charges and in a reduced charge-selectivity of the
glomerular barrier.36 Synthesis of proteoglycans occurs in all
three glomerular cell types, in particular podocytes, and, in
vitro, is inhibited by high ambient glucose and angiotensin
II.37,38 Thus, hyperglycemia and activation of the renin
angiotensin system (RAS) might contribute to a loss of
charge-dependent restriction of macromolecule filtration at
the glomerulus that might facilitate albumin ultrafiltration.
Alternatively, glycosylation of circulating albumin may shift
its net charge toward a more neutral range. An increase in the
charge microheterogeneity of serum albumin – with an
increase in the isoelectric point – has been described in
adolescents with diabetes.39 Cationization of albumin
changes its spatial configuration40 and may thus also
influence its size-based exclusion by the capillary wall39 or
increase its binding to the negatively charged brush border of
proximal tubule cells, thereby increasing its reabsorption.41
Finally, albumin glycosylation cannot explain enhanced
albuminuria in obese or hypertensive subjects with decreased
insulin sensitivity, but no overt diabetes.
Albuminuria may be the consequence of decreased
albumin re-uptake at tubular level. Endocytotic uptake of
albumin by proximal tubular cells in culture is regulated by
phosphatidyl inositide 3-kinase,42 an enzyme that in
proximal tubule cell cultures is activated by insulin. This
suggests that insulin might increase albumin endocytosis,
possibly by stimulating interaction of clathrin-coated pits
with the endosome compartment. The development of
insulin resistance may therefore adversely effect tubular
albumin uptake and lead to excretion of a larger fraction of
the albumin that is filtered at the glomerulus.
The independent role of glomerular hyperfiltration
Perfusion of physiological concentrations of insulin into
isolated rat kidneys induces vasodilatation and increases the
glomerular filtration rate by a prostaglandin-dependent
process.43 In normal rats, acute hyperinsulinemia increases
the renal plasma flow and the glomerular hydrostatic pressure
gradient via a preferential dilatation of the afferent
arteriole.44 In genetically obese rats, the glomerular filtration
rate (GFR) is increased and starts to decrease only with the
development of overt proteinuria.45 In humans, hyperinsu-
linemia is a typical component of the insulin-resistance
syndrome that may affect subjects with obesity, hypertension,
or type II diabetes.46 Insulin resistance, estimated by the
glucose-clamp technique, is positively correlated with
glomerular filtration fraction and is associated with glomeru-
lar hyperfiltration.47 Thus, insulin resistance and secondary
hyperinsulinemia may cause glomerular hypertension and
hyperfiltration, which, in turn, may enhance albumin
ultrafiltration and excretion. Actually, severe obesity – a
condition characterized by decreased insulin sensitivity 46 – is
associated with high renal plasma flow,48,49 increased
GFR,48,50 and enhanced urinary albumin excretion.51,52
Analyses of dextran sieving data showed that the glomerular
capillary bed of obese subjects is exposed to increased
perfusion and elevated transcapillary hydraulic pressure
resulting in hyperfiltration and increased albuminuria.53
These functional abnormalities – that reflect a state of renal
vasodilation involving, mainly or solely, the afferent arteriole
– are particularly prominent in subjects with abdominal
obesity – a condition associated with severe insulin resistance
and the metabolic syndrome52,54 – and may fully recover with
weight loss.55 Thus, the kidney of insulin-resistant subjects
shears functional abnormalities with the kidney of overt
diabetics and, as the diabetic kidney, is susceptible to damage
and eventual development of overt proteinuria and glomerulo-
sclerosis.56
Insulin resistance may also affect the GFR via its effects on
systemic blood pressure. Hyperinsulinemia sustains salt- and
volume-dependent hypertension by directly promoting
sodium and water reabsorption at tubular level,57 by
activating the sympathetic nervous system activity,58 and by
inducing endothelial dysfunction (see above). Systemic
hypertension may then contribute to glomerular hyperten-
sion and increased albumin ultrafiltration, in particular when
insulin-induced pre-glomerular vasodilation facilitates the
transmission of the systemic blood pressure to the glomerular
capillary.44 Concomitant endothelial dysfunction might also
enhance glomerular susceptibility to the mechanical insult.28
On the other end, a direct effect of insulin on glomerular
permeability is unlikely, as physiological hyperinsulinemia
does not increase albumin transcapillary escape in healthy
subjects, as well as in patients with type II diabetes.25 The
increased albuminuria observed in some studies during acute
hyperinsulinemia may therefore reflect increased sympathetic
activity,58 blood volume contraction,25 or decreased tubular
albumin reabsorption.25
Consistent with a specific role for insulin resistance in the
pathogenesis of glomerular hyperfiltration and albuminuria
is the evidence that amelioration of insulin reduced the GFR
and UAE in subjects with type II diabetes and microalbumin-
uria.34 The significant, positive correlation between changes
in GFR and albuminuria did also suggest the possibility of a
cause and effect relationship between amelioration of
glomerular hyperfiltration and reduction of albuminuria.
Indeed, theoretical models of albumin reabsorption in the
proximal tubule59 suggest that glomerular hyperfiltration
may result in increased UAE even in the absence of size/
charge-selective dysfunction of the glomerular barrier or of
intrinsic abnormalities of tubular albumin endocytosis. In
experimental animals, ultrafiltered albumin is largely reab-
sorbed in the proximal tubule41,60 via an endocytic mechan-
ism initiated by albumin binding to surface-expressed
glycoproteins megalin and cubulin that colocalize in
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endocytic pits.61,62 Should this mechanism be inhibited, up
to 90% of ultrafiltered albumin would be lost in urine.41,60 If
the same relationship were to hold in humans, then abolition
of tubular reabsorption alone could result in up to 300 mg/
24 h of albuminuria.17
In addition to receptor expression and kinetics, the rate of
albumin reabsorption depends also on physical processes
within the tubule lumen. For cellular uptake to occur,
albumin must diffuse and/or be convected radially from the
bulk tubule fluid to the endocytic pits at the bases of the
microvilli. Accordingly, mass transfer resistances in the open
part of the lumen and in the intermicrovillar fluid potentially
limit the overall rate of albumin reabsorption. Moreover, the
axial flow rate may influence how rapidly the albumin
concentration falls along the tubule. When the single
nephron GFR increases and more fluid is ultrafiltered
through the glomerular barrier, the flow rate through the
tubule increases and the residence time for albumin in the
tubule decreases. Thus, the available time at tubular surface
to bind and reabsorb ultrafiltered albumin decreases and the
overall amount of reabsorbed albumin tends to be reduced.
Moreover, when the fluid rate increases, the radial gradient of
albumin concentration within the tubule may also increase
and lower amounts of ultrafiltered albumin may diffuse
from the tubule axis to the tubule surface. This may further
limit tubular albumin reabsorption and contribute to
increase UAE.
Thus, the albuminuria often observed in hyperinsulinemic
subjects with obesity, hypertension, or diabetes might be
explained by functional – and potentially reversible –
disturbances in proximal tubule albumin reabsorption
initiated by glomerular hyperfiltration. This is consistent
with functional studies showing no abnormalities in
glomerular size-selective function in type I63 and type II17
diabetic subjects with microalbuminuria and with morpho-
logical studies showing that no structural abnormalities
beyond glomerular hypertrophy, mild increases in mesangial
volume fraction, and basement membrane thickness are
detected in kidney tissue from obese Pima Indians17 or
Caucasians (A Remuzzi, personal communication) with type
II diabetes and microalbuminuria.
ALBUMINURIA AND THE CARDIO-RENAL SYNDROME: IS
NEPHRON UNDERDOSING THE LINK?
Albuminuria is strongly associated with the metabolic
syndrome.64 Thus, the predictive role of albuminuria might
be easily explained by the well-established association
between the metabolic syndrome and increased renal and
cardiovascular morbidity.64,65 According to the Steno hypo-
thesis,29 albuminuria might reflect a general vascular
dysfunction, and leakage of albumin and other plasma
macromolecules such as low-density lipoproteins into the
vessel wall may lead to inflammatory responses that in turn
may start the atherosclerotic process. Moreover, the increased
microvascular pressures and flows observed in diabetes and
hypertension may act as injurious stimuli to the endothelium
(hemodynamic hypothesis), leading to impaired vasodilatory
function, excess matrix protein production, capillary base-
ment membrane thickening, and sclerosis. In the heart, this
may contribute to the impaired coronary hemodynamics
associated with adaptative left ventricular hypertrophy and
the consequent diminution of coronary reserve, increasing
diffusion distances, failure of angiogenesis to compensate,
and secondary ischemic myocyte injury.66
An attractive hypothesis is that a reduced nephron
number at birth, ‘nephron underdosing’, might predispose
to both renal and cardiovascular disease.67 Aberrant fetal
programming by genetic factors, malnutrition, and other
insults to the pregnant mother might lead to less glomeruli.
This might predispose to glomerular hyperfiltration, hyper-
tension, albuminuria, and renal disease. According to Backer
hypothesis this might also predispose to the metabolic
syndrome and cardiovascular events in adult life.68 Indeed,
the relation between less nephrons and hypertension has been
proven.69 Suggestive, although not definitive, evidence for a
link between fetal malnutrition and albuminuria is also
available.70 Thus, reduced nephron number at birth might be
the common determinant of hyperfiltration and insulin
resistance. Hyperfiltration and insulin resistance may both
predispose to the development of albuminuria, in particular
in concomitance with other components of the metabolic
syndrome such as hypertension, obesity, or diabetes that may
contribute to worsen glomerular dysfunction. In a propor-
tion of patients, albuminuria will precede the onset of clinical
proteinuria and the metabolic syndrome will predict an
increased risk of cardiovascular events (Figure 1). In turn,
albuminuria may be sustained by the inflammatory status
that accompanies macrovascular disease.71
Regardless of the above, screening for albuminuria may be
the most effective way to early identify subjects who are at
increased risk for both renal and cardiovascular events. Other
approaches to detect high-risk patients at even earlier stages
might include screening for hyperfiltration or decreased
insulin sensitivity. Reliable markers of hyperfiltration that can
be used for population screenings, however, are missing. The
homeostasis model assessment index72 may be used to
identify those who are insulin resistant. However, the
predictive value of this marker for cardiovascular events is,
so far, not established. Dipstick for albuminuria is easy and
inexpensive, and remains the most practical way to identify
subjects at risk.
WHY SHOULD PROTEINURIA INITIATE PROGRESSIVE RENAL
AND CARDIOVASCULAR DISEASE?
The National Health and Nutrition Examination Survey III
found that the metabolic syndrome is a strong and
independent risk factor for chronic kidney disease.64 These
findings extend previous evidence that the metabolic
syndrome is associated with an increased risk for diabetes,
cardiovascular disease, as well as increased mortality from
cardiovascular disease and all causes in the general popula-
tion.65 Longitudinal studies of the time course of GFR in type
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I diabetes clearly show that, without treatment beyond blood
glucose control, after several years of stable renal function,
the GFR starts to decline in parallel with the appearance of
macroalbuminuria.73 Studies in the Pima Indians confirm
that the GFR remains elevated until macroalbuminuria
develops also in type II diabetes.74,75 At this stage, the
glomerular barrier becomes more restrictive except for the
passage of large, nearly impermeant dextrans, suggesting a
loss of ultrafiltration capacity and the formation of a
shunt.17,75 Thus, enhanced and unrestricted ultrafiltration
of plasma macromolecules – including not only albumin but
also other plasma proteins, immunoglobulins, growth
factors, and complement components all of which have a
specific nephrotoxicity – may initiate a self-perpetuating
process of progressive glomerulosclerosis, tubulointerstitial
inflammation, and scarring, with progressive renal function
loss, in both diabetic and non-diabetic chronic renal disease
(Figure 1).76 Actually, altered protein traffic can exert local
effects which are rather related to the nature of a given
filtered protein. For example, critical amounts of transfer-
ring–iron complexes at the local acidic pH of proximal
tubular fluid may release iron, which in turn promotes lipid
peroxidative damage to the cytosol and cell membrane.77
After filtration, insulin-like growth factor 1 dissociates from
binding proteins and stimulates mitogenesis and synthesis of
collagen I and IV in proximal tubular cells.77,78 An additional
mechanism directly relevant to inflammatory events can be
mediated by a chemotactic lipid factor isolated from urine of
rats with overload proteinuria.79 A factor with identical
biochemical features is released by proximal tubules exposed
to fatty acid bound to albumin as a probable consequence of
changes in the epithelial cell phenotype linked to the
metabolism of lipoproteins.80 Ultrafiltered complement
components can also form deposits along the luminal side
of proximal tubular cells in rats with protein overload
nephropathy, aminonucleoside nephrosis, and remnant
kidneys,76 a pattern that is commonly observed in kidneys
of patients with proteinuria and correlates with urinary
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Figure 1 | Time course of albuminuria/proteinuria and GFR in a hypothetical subject at increased risk of renal or cardiovascular events
because of insulin resistance and endothelial dysfunction. In a predisposed patient, possibly because of a reduced nephron number at
birth, the development of insulin resistance and of the metabolic syndrome may induce and sustain a progressive increase in the GFR. Initially,
this hemodynamic abnormality is fully reversible, may be transiently exacerbated by hyperglycemia, hypertension, or high protein intake, and is
not associated with functional or structural abnormalities of the glomerular barrier. With time, a further increase of the GFR may per se sustain a
progressive increase in albuminuria mediated by physical processes within the tubule that may be independent of sieving defects of the
glomerular barrier. Prolonged exposure to increased intracapillary pressures, hyperglycemia, and hyperinsulinemia may progressively affect the
sieving function of the glomerular barrier, which may increase albumin ultrafiltration and albuminuria. At this stage, structural abnormalities of
the mesangium and of the glomerular barrier may become apparent, but glomerulosclerosis is still not evident. Without treatment, these
functional and structural changes may progress and a shunt may appear that allows for the ultrafiltration of larger plasma macromolecules,
including proteins other than albumin, growth factors, lipoproteins, and complement components. The enhanced traffic of these plasma
components may sustain a self-perpetuating process of chronic inflammation and scarring that results in a relentless renal function loss and
progression to end-stage renal disease. Diffuse glomerulosclerosis and tubulo-interstitial fibrosis become apparent. Throughout the stage of
glomerular hyperfiltration and albuminuria, the cardiovascular risk may be increased because of the concomitance of the metabolic syndrome
(obesity, hypertension, diabetes, dyslipidemia). With the appearance of proteinuria and renal insufficiency, renal dysfunction contributes to
further enhance the cardiovascular risk to such an extent that the majority of subjects will die of cardiovascular events before progressing to
end-stage renal disease. Albuminuria is therefore the marker of an excess risk associated with the metabolic syndrome and its components
(albuminuria-associated disease). Proteinuria is an independent determinant of progressive renal and cardiovascular damage, which
independently contributes to further increase the risk (proteinuria-associated disease).
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complement excretion. C3 and C5b-9 can promote tubular
injury and interstitial inflammation by generating oxygen-
free radicals and chemotactic gradients.76
Proteinuria is usually associated with extensive mesangial
expansion and glomerulosclerosis, in particular in obese, type
II diabetic subjects.17,75 Mesangial expansion might impinge
on the peripheral capillaries of patent glomeruli, further
reducing the surface area available for filtration.81 In
addition, the thickening of the basement membrane and
the widening of epithelial foot processes may reduce the
hydraulic permeability of the glomerulus,82 indicating that
the decline in ultrafiltration capacity is due both to a loss of
filtration area and to a reduction in glomerular hydraulic
permeability.83 The volume of the remaining open glomeruli
progressively increases, perhaps as a means of compensating
for the loss of filtration area and hydraulic permeability.
Hyperperfusion and hyperfiltration of these remnant glo-
meruli may compensate for the loss of the ultrafiltration
capacity. Glomerular filtration declines rapidly when the
glomerular hyperperfusion can no longer compensate for the
loss of ultrafiltration capacity.74 Declining GFR and worsen-
ing proteinuria aggravate the metabolic syndrome and
accelerate atherosclerosis and cardiovascular disease, which
contributes to the dramatic excess cardiovascular morbidity
and mortality associated with chronic kidney disease.16,64
Altogether, these data lend support to the hypothesis that,
with proteinuria, the appearance in the urine of plasma
proteins different from albumin identifies the progression
from functional and potentially reversible abnormalities to
persistent functional and structural changes that, without
treatment, sustain a relentless progression to end-stage renal
disease.75 This is consistent with evidence that, among
primary chronic glomerular diseases associated with protei-
nuria, the only one that is normally not characterized by
progressive renal function loss and irreversible kidney
structural damage is ‘nihil’ disease, a condition normally
associated with ‘pure’ albuminuria.84 In those subjects with
progressive renal function deterioration, urinalysis invariably
shows plasma proteins also different from albumin and
clearance studies disclose the appearance of a shunt
allowing for an unrestricted ultrafiltration of plasma
macromolecules.84 At this stage, morphological evaluation
of the kidney tissue identifies the appearance of diffuse
glomerulosclerosis and tubulointerstitial infiltration,
typical features of progressive nephropathies associated
with proteinuria.17,85 The pathogenic role of proteinuria is
suggested by animal and human studies showing that
drugs, such as angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers, that ameliorate the
glomerular sieving function and reduce the shunt pathway,
in addition to restrict the ultrafiltration of larger plasma
macromolecules, prevent progressive kidney damage and
renal function loss.86–90
Thus, given that substantial kidney dysfunction and
structural damage are not evident before the development
of proteinuria, therapeutic interventions aimed at preventing
renal and cardiovascular disease might have their greatest
beneficial effects in those subjects who have not yet developed
macroalbuminuria.
REDUCING ALBUMINURIA: AN EFFECTIVE WAY TO PREVENT
RENAL AND CARDIOVASCULAR DISEASE?
Multimodal treatment targeting urinary proteins, blood
pressure, lipids, and glucose (in diabetics) may achieve
remission of proteinuria and stabilization of renal function in
a substantial proportion of subjects with proteinuric renal
disease,91 which may translate in a remarkable reduction in
cardiovascular and all-cause mortality.92 In about two-thirds
of those with diabetes92 and one-third of those without,91
however, remission is not achieved and renal and cardiovas-
cular risk remain elevated. Thus, early intervention, started
before progressive glomerulosclerosis and scarring is initiated
by increased protein traffic, may be important to maximize
reno- and cardioprotection. In diabetes, there is no doubt
that therapies that prevent or delay the development of
macroalbuminuria are beneficial. The Irbesartan in Patients
with type II Diabetes and Microalbuminuria showed that
inhibition of the RAS by the angiotensin II receptor blocker
irbesartan slowed the progression to overt nephropathy and
was associated with a reduced number of cardiovascular
events as compared to non-RAS inhibitor antihypertensive
therapy.93 In the BErgamo NEphrologic Diabetes Complica-
tions Trial study, RAS-inhibition by the angiotensin-convert-
ing enzyme inhibitor trandolapril, added-on optimized
metabolic and blood pressure control by non-RAS inhibitor
therapy, halved the risk of developing microalbuminuria in
subjects with type II diabetes and arterial hypertension, but
no evidence of renal disease.12 This effect exceeded the benefit
expected on the basis of blood pressure reduction alone.
Notably, regardless of treatment randomization, only 13 of
1204 randomized patients died of cardiovascular disease over
a median follow-up of 3.6 years. This mortality rate (0.3%
per year) was 26-fold lower the rate (7.9% per year) observed
– over a comparable observation period and at a comparable
blood pressure control – in type II diabetic patients with
macroalbuminuria included in the Reduction in Endpoints in
Non-insulin-dependent diabetes mellitus with the Angioten-
sin II receptor Antagonist Losartan study.90 Consistently, the
Heart Outcome Prevention Evaluation and Losartan Inter-
vention For End point reduction in hypertension trials8,9
found that albuminuria reduction from baseline to losartan
or ramipril treatment, respectively, predicted delayed pro-
gression to overt nephropathy and cardiovascular protection
on follow-up. Finally, the Prevention of Renal and Vascular
Endstage Disease Intervention Trial found less cardiovascular
events in subjects with increased albuminuria on angioten-
sin-converting enzyme inhibitor therapy as compared to
controls on non-RAS inhibitor therapy.94 Altogether these
data, indirectly, highlight the importance of early interven-
tion, not only to prevent the onset of overt nephropathy and
subsequent progression to ESRD but also to limit the excess
cardiovascular morbidity and mortality associated with
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proteinuria and progressive renal insufficiency, in subjects
with or without diabetes.
CONCLUSION
Here we suggest that albuminuria is a marker of glomerular
hyperfiltration. The frequent association of this functional
and potentially reversible abnormality that is often associated
with the metabolic syndrome. This likely may explain why
albuminuria is also an early marker of increased renal
and cardiovascular risk. Among subjects with albuminuria,
any degree of measurable albuminuria bears a significant
risk for renal and cardiovascular events. Data from Heart
Outcome Prevention Evaluation, Losartan Intervention
For End point reduction in hypertension, and Framingham
studies8,9,13 clearly suggest that only negligible amounts of
albuminuria below approximately 2 mg/g of urinary
creatinine (or an estimated excretion rate of 2 mg/day)
should be considered as ‘normal’. This approximately
corresponds to a urinary concentration of 1–2 mg/ml, which
is below or close to the detection limit of the methods
commonly used for the measurement of urinary albumin
such as nephelometry and immunoturbidimetry. Indeed,
values above this threshold are significantly associated with
risk for overt nephropathy, myocardial infarction, and
cardiovascular death. The Heart Outcome Prevention
Evaluation and Losartan Intervention For End point reduc-
tion in hypertension results further suggest that this
association applies to diabetics and non-diabetics, alike.8,9
This may have major practical implications as albuminuria
can be ameliorated by amelioration of insulin sensitivity,34
weight loss,55 blood pressure and blood glucose reduc-
tion,95,96 and RAS-inhibitor therapy.8,9,12,93 In the long run,
these interventions are expected to prevent or delay end-
organ damage. Once proteinuria heralds the onset of overt
kidney damage, a self-perpetuating process of progressive
renal dysfunction and accelerated atherosclerosis is initiated
that dramatically increases the overall renal and cardiovas-
cular risk. At this stage, multimodal regimens targeted at
urinary proteins, blood pressure, lipids, and blood glucose91
may reduce the risk, but may seldom achieve full remission of
kidney disease and effective prevention of cardiovascular risk,
in particular in those with type II diabetes and overt
nephropathy.92 Thus, evaluating not only the amount of
albuminuria but also the newly onset of proteinuria may help
to better characterize the risk and to guide renal and
cardioprotective therapy. To this purpose, the terms micro-
albuminuria and macroalbuminuria could be abandoned and
replaced by the concepts of albuminuria- and proteinuria-
associated diseases. Future randomized trials are needed to
identify levels of albuminuria below which further therapy is
no longer beneficial.
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